Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Acid microenvironment promotes cell survival of human bone sarcoma through the activation of cIAP proteins and NF-κB pathway.

Avnet S, Chano T, Massa A, Bonuccelli G, Lemma S, Falzetti L, Grisendi G, Dominici M, Baldini N.

Am J Cancer Res. 2019 Jun 1;9(6):1127-1144. eCollection 2019.

2.

A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX.

Sotgia F, Ozsvari B, Fiorillo M, De Francesco EM, Bonuccelli G, Lisanti MP.

Cell Cycle. 2018;17(17):2091-2100. doi: 10.1080/15384101.2018.1515551. Epub 2018 Sep 26.

3.
4.

Mitochondrial fission as a driver of stemness in tumor cells: mDIVI1 inhibits mitochondrial function, cell migration and cancer stem cell (CSC) signalling.

Peiris-Pagès M, Bonuccelli G, Sotgia F, Lisanti MP.

Oncotarget. 2018 Jan 19;9(17):13254-13275. doi: 10.18632/oncotarget.24285. eCollection 2018 Mar 2.

5.

Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy.

Ozsvari B, Bonuccelli G, Sanchez-Alvarez R, Foster R, Sotgia F, Lisanti MP.

Aging (Albany NY). 2017 Dec 16;9(12):2610-2628. doi: 10.18632/aging.101351.

6.

Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast.

Ozsvari B, Fiorillo M, Bonuccelli G, Cappello AR, Frattaruolo L, Sotgia F, Trowbridge R, Foster R, Lisanti MP.

Oncotarget. 2017 Jul 7;8(40):67457-67472. doi: 10.18632/oncotarget.19084. eCollection 2017 Sep 15.

7.

Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs).

De Francesco EM, Bonuccelli G, Maggiolini M, Sotgia F, Lisanti MP.

Oncotarget. 2017 Jun 9;8(40):67269-67286. doi: 10.18632/oncotarget.18428. eCollection 2017 Sep 15.

8.

NADH autofluorescence, a new metabolic biomarker for cancer stem cells: Identification of Vitamin C and CAPE as natural products targeting "stemness".

Bonuccelli G, De Francesco EM, de Boer R, Tanowitz HB, Lisanti MP.

Oncotarget. 2017 Mar 28;8(13):20667-20678. doi: 10.18632/oncotarget.15400.

9.

Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.

Bonuccelli G, Peiris-Pages M, Ozsvari B, Martinez-Outschoorn UE, Sotgia F, Lisanti MP.

Oncotarget. 2017 Feb 7;8(6):9868-9884. doi: 10.18632/oncotarget.14196.

10.

Tumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion.

Cortini M, Massa A, Avnet S, Bonuccelli G, Baldini N.

PLoS One. 2016 Nov 16;11(11):e0166500. doi: 10.1371/journal.pone.0166500. eCollection 2016.

11.

Tumour-specific metabolic adaptation to acidosis is coupled to epigenetic stability in osteosarcoma cells.

Chano T, Avnet S, Kusuzaki K, Bonuccelli G, Sonveaux P, Rotili D, Mai A, Baldini N.

Am J Cancer Res. 2016 Mar 15;6(4):859-75. eCollection 2016.

12.

Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling.

Lamb R, Bonuccelli G, Ozsvári B, Peiris-Pagès M, Fiorillo M, Smith DL, Bevilacqua G, Mazzanti CM, McDonnell LA, Naccarato AG, Chiu M, Wynne L, Martinez-Outschoorn UE, Sotgia F, Lisanti MP.

Oncotarget. 2015 Oct 13;6(31):30453-71. doi: 10.18632/oncotarget.5852.

13.

Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment.

Perut F, Carta F, Bonuccelli G, Grisendi G, Di Pompo G, Avnet S, Sbrana FV, Hosogi S, Dominici M, Kusuzaki K, Supuran CT, Baldini N.

Expert Opin Ther Targets. 2015;19(12):1593-605. doi: 10.1517/14728222.2016.1086339. Epub 2015 Sep 10.

PMID:
26357839
14.

Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells.

Lamb R, Ozsvari B, Bonuccelli G, Smith DL, Pestell RG, Martinez-Outschoorn UE, Clarke RB, Sotgia F, Lisanti MP.

Oncotarget. 2015 Sep 8;6(26):21892-905.

15.

Impairment of lysosomal activity as a therapeutic modality targeting cancer stem cells of embryonal rhabdomyosarcoma cell line RD.

Salerno M, Avnet S, Bonuccelli G, Hosogi S, Granchi D, Baldini N.

PLoS One. 2014 Oct 20;9(10):e110340. doi: 10.1371/journal.pone.0110340. eCollection 2014.

16.

Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells.

Bonuccelli G, Avnet S, Grisendi G, Salerno M, Granchi D, Dominici M, Kusuzaki K, Baldini N.

Oncotarget. 2014 Sep 15;5(17):7575-88.

17.

Sphere-forming cell subsets with cancer stem cell properties in human musculoskeletal sarcomas.

Salerno M, Avnet S, Bonuccelli G, Eramo A, De Maria R, Gambarotti M, Gamberi G, Baldini N.

Int J Oncol. 2013 Jul;43(1):95-102. doi: 10.3892/ijo.2013.1927. Epub 2013 May 1.

PMID:
23636271
18.

Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs.

Araujo KP, Bonuccelli G, Duarte CN, Gaiad TP, Moreira DF, Feder D, Belizario JE, Miglino MA, Lisanti MP, Ambrosio CE.

PLoS One. 2013 Apr 8;8(4):e61367. doi: 10.1371/journal.pone.0061367. Print 2013.

19.

V-ATPase is a candidate therapeutic target for Ewing sarcoma.

Avnet S, Di Pompo G, Lemma S, Salerno M, Perut F, Bonuccelli G, Granchi D, Zini N, Baldini N.

Biochim Biophys Acta. 2013 Aug;1832(8):1105-16. doi: 10.1016/j.bbadis.2013.04.003. Epub 2013 Apr 8.

20.

Cav1 suppresses tumor growth and metastasis in a murine model of cutaneous SCC through modulation of MAPK/AP-1 activation.

Trimmer C, Bonuccelli G, Katiyar S, Sotgia F, Pestell RG, Lisanti MP, Capozza F.

Am J Pathol. 2013 Mar;182(3):992-1004. doi: 10.1016/j.ajpath.2012.11.008. Epub 2012 Dec 22.

21.

The milk protein α-casein functions as a tumor suppressor via activation of STAT1 signaling, effectively preventing breast cancer tumor growth and metastasis.

Bonuccelli G, Castello-Cros R, Capozza F, Martinez-Outschoorn UE, Lin Z, Tsirigos A, Xuanmao J, Whitaker-Menezes D, Howell A, Lisanti MP, Sotgia F.

Cell Cycle. 2012 Nov 1;11(21):3972-82. doi: 10.4161/cc.22227. Epub 2012 Oct 9.

22.

Metabolic remodeling of the tumor microenvironment: migration stimulating factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth.

Carito V, Bonuccelli G, Martinez-Outschoorn UE, Whitaker-Menezes D, Caroleo MC, Cione E, Howell A, Pestell RG, Lisanti MP, Sotgia F.

Cell Cycle. 2012 Sep 15;11(18):3403-14. doi: 10.4161/cc.21701. Epub 2012 Aug 23.

23.

Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production.

Capparelli C, Guido C, Whitaker-Menezes D, Bonuccelli G, Balliet R, Pestell TG, Goldberg AF, Pestell RG, Howell A, Sneddon S, Birbe R, Tsirigos A, Martinez-Outschoorn U, Sotgia F, Lisanti MP.

Cell Cycle. 2012 Jun 15;11(12):2285-302. doi: 10.4161/cc.20718. Epub 2012 Jun 15.

24.

Caveolin-1 promotes pancreatic cancer cell differentiation and restores membranous E-cadherin via suppression of the epithelial-mesenchymal transition.

Salem AF, Bonuccelli G, Bevilacqua G, Arafat H, Pestell RG, Sotgia F, Lisanti MP.

Cell Cycle. 2011 Nov 1;10(21):3692-700. doi: 10.4161/cc.10.21.17895. Epub 2011 Nov 1.

25.

Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis.

Castello-Cros R, Bonuccelli G, Molchansky A, Capozza F, Witkiewicz AK, Birbe RC, Howell A, Pestell RG, Whitaker-Menezes D, Sotgia F, Lisanti MP.

Cell Cycle. 2011 Jun 15;10(12):2021-34. Epub 2011 Jun 15.

26.

The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox.

Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, Chiavarina B, Bonuccelli G, Casey T, Tsirigos A, Migneco G, Witkiewicz A, Balliet R, Mercier I, Wang C, Flomenberg N, Howell A, Lin Z, Caro J, Pestell RG, Sotgia F, Lisanti MP.

Cell Cycle. 2010 Nov 1;9(21):4297-306. Epub 2010 Nov 30. Review.

27.

Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism.

Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, Frank PG, Flomenberg N, Howell A, Martinez-Outschoorn UE, Sotgia F, Lisanti MP.

Cell Cycle. 2010 Sep 1;9(17):3506-14. Epub 2010 Sep 21.

28.

CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway.

Trimmer C, Whitaker-Menezes D, Bonuccelli G, Milliman JN, Daumer KM, Aplin AE, Pestell RG, Sotgia F, Lisanti MP, Capozza F.

Cancer Res. 2010 Oct 1;70(19):7489-99. doi: 10.1158/0008-5472.CAN-10-0900. Epub 2010 Aug 13.

29.

The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts.

Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Witkiewicz AK, Vander Heiden MG, Migneco G, Chiavarina B, Frank PG, Capozza F, Flomenberg N, Martinez-Outschoorn UE, Sotgia F, Lisanti MP.

Cell Cycle. 2010 May 15;9(10):1960-71. Epub 2010 May 15.

PMID:
20495363
30.

Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies.

Gazzerro E, Assereto S, Bonetto A, Sotgia F, Scarfì S, Pistorio A, Bonuccelli G, Cilli M, Bruno C, Zara F, Lisanti MP, Minetti C.

Am J Pathol. 2010 Apr;176(4):1863-77. doi: 10.2353/ajpath.2010.090468. Epub 2010 Mar 19.

31.

Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth.

Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Addya S, Fortina P, Dasgupta A, Hyslop T, Bubendorf L, Nevalainen MT.

Am J Pathol. 2010 Apr;176(4):1959-72. doi: 10.2353/ajpath.2010.090653. Epub 2010 Feb 18.

32.

Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy.

Witkiewicz AK, Casimiro MC, Dasgupta A, Mercier I, Wang C, Bonuccelli G, Jasmin JF, Frank PG, Pestell RG, Kleer CG, Sotgia F, Lisanti MP.

Cell Cycle. 2009 Jun 1;8(11):1654-8.

PMID:
19448435
33.

Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature.

Bonuccelli G, Casimiro MC, Sotgia F, Wang C, Liu M, Katiyar S, Zhou J, Dew E, Capozza F, Daumer KM, Minetti C, Milliman JN, Alpy F, Rio MC, Tomasetto C, Mercier I, Flomenberg N, Frank PG, Pestell RG, Lisanti MP.

Am J Pathol. 2009 May;174(5):1650-62. doi: 10.2353/ajpath.2009.080648.

34.

Using Caveolin-1 epithelial immunostaining patterns to stratify human breast cancer patients and predict the Caveolin-1 (P132L) mutation.

Mercier I, Bryant KG, Sotgia F, Bonuccelli G, Witkiewicz AK, Dasgupta A, Jasmin JF, Pestell RG, Lisanti MP.

Cell Cycle. 2009 May 1;8(9):1396-401. Epub 2009 May 26.

PMID:
19342880
35.

Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions.

Mercier I, Casimiro MC, Zhou J, Wang C, Plymire C, Bryant KG, Daumer KM, Sotgia F, Bonuccelli G, Witkiewicz AK, Lin J, Tran TH, Milliman J, Frank PG, Jasmin JF, Rui H, Pestell RG, Lisanti MP.

Am J Pathol. 2009 Apr;174(4):1172-90. doi: 10.2353/ajpath.2009.080882.

36.

Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts.

Sotgia F, Del Galdo F, Casimiro MC, Bonuccelli G, Mercier I, Whitaker-Menezes D, Daumer KM, Zhou J, Wang C, Katiyar S, Xu H, Bosco E, Quong AA, Aronow B, Witkiewicz AK, Minetti C, Frank PG, Jimenez SA, Knudsen ES, Pestell RG, Lisanti MP.

Am J Pathol. 2009 Mar;174(3):746-61. doi: 10.2353/ajpath.2009.080658.

37.

Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation.

Sotgia F, Casimiro MC, Bonuccelli G, Liu M, Whitaker-Menezes D, Er O, Daumer KM, Mercier I, Witkiewicz AK, Minetti C, Capozza F, Gormley M, Quong AA, Rui H, Frank PG, Milliman JN, Knudsen ES, Zhou J, Wang C, Pestell RG, Lisanti MP.

Am J Pathol. 2009 Feb;174(2):613-29. doi: 10.2353/ajpath.2009.080653.

38.

Stat3 promotes metastatic progression of prostate cancer.

Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Nevalainen MT.

Am J Pathol. 2008 Jun;172(6):1717-28. doi: 10.2353/ajpath.2008.071054. Epub 2008 May 15.

39.

Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy.

Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Minkeu A, Allen KG, Danilo C, Sotgia F, Bonuccelli G, Jasmin JF, Xu H, Bosco E, Aronow B, Witkiewicz A, Pestell RG, Knudsen ES, Lisanti MP.

Cancer Biol Ther. 2008 Aug;7(8):1212-25. Epub 2008 Aug 30.

40.

Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice.

Bonuccelli G, Sotgia F, Capozza F, Gazzerro E, Minetti C, Lisanti MP.

Cell Cycle. 2007 May 15;6(10):1242-8. Epub 2007 May 27.

PMID:
17495527
41.

Anthrax lethal toxin kills macrophages in a strain-specific manner by apoptosis or caspase-1-mediated necrosis.

Muehlbauer SM, Evering TH, Bonuccelli G, Squires RC, Ashton AW, Porcelli SA, Lisanti MP, Brojatsch J.

Cell Cycle. 2007 Mar 15;6(6):758-66. Epub 2007 Mar 7.

PMID:
17374996
42.

Caveolin-1(-/-)- and caveolin-2(-/-)-deficient mice both display numerous skeletal muscle abnormalities, with tubular aggregate formation.

Schubert W, Sotgia F, Cohen AW, Capozza F, Bonuccelli G, Bruno C, Minetti C, Bonilla E, Dimauro S, Lisanti MP.

Am J Pathol. 2007 Jan;170(1):316-33.

43.

Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers.

Sotgia F, Rui H, Bonuccelli G, Mercier I, Pestell RG, Lisanti MP.

Cancer Res. 2006 Nov 15;66(22):10647-51. Review.

44.

Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells.

Williams TM, Sotgia F, Lee H, Hassan G, Di Vizio D, Bonuccelli G, Capozza F, Mercier I, Rui H, Pestell RG, Lisanti MP.

Am J Pathol. 2006 Nov;169(5):1784-801.

45.

Caveolin-1-deficient mice show defects in innate immunity and inflammatory immune response during Salmonella enterica serovar Typhimurium infection.

Medina FA, de Almeida CJ, Dew E, Li J, Bonuccelli G, Williams TM, Cohen AW, Pestell RG, Frank PG, Tanowitz HB, Lisanti MP.

Infect Immun. 2006 Dec;74(12):6665-74. Epub 2006 Sep 18.

46.

Pharmacological rescue of the dystrophin-glycoprotein complex in Duchenne and Becker skeletal muscle explants by proteasome inhibitor treatment.

Assereto S, Stringara S, Sotgia F, Bonuccelli G, Broccolini A, Pedemonte M, Traverso M, Biancheri R, Zara F, Bruno C, Lisanti MP, Minetti C.

Am J Physiol Cell Physiol. 2006 Feb;290(2):C577-82. Epub 2005 Sep 28.

47.

TEM8 expression stimulates endothelial cell adhesion and migration by regulating cell-matrix interactions on collagen.

Hotchkiss KA, Basile CM, Spring SC, Bonuccelli G, Lisanti MP, Terman BI.

Exp Cell Res. 2005 Apr 15;305(1):133-44.

PMID:
15777794
48.

ATR/TEM8 is highly expressed in epithelial cells lining Bacillus anthracis' three sites of entry: implications for the pathogenesis of anthrax infection.

Bonuccelli G, Sotgia F, Frank PG, Williams TM, de Almeida CJ, Tanowitz HB, Scherer PE, Hotchkiss KA, Terman BI, Rollman B, Alileche A, Brojatsch J, Lisanti MP.

Am J Physiol Cell Physiol. 2005 Jun;288(6):C1402-10. Epub 2005 Feb 2.

49.
50.

Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins.

Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, Woodman SE, Insabato L, Cammer M, Minetti C, Lisanti MP.

Am J Pathol. 2003 Oct;163(4):1663-75.

Supplemental Content

Loading ...
Support Center